Amir Anthony Jazaeri, M.D.

Peer-Reviewed Articles

1. Brodsky, AL, Asare, A, Fellman, B, Anderson, K, Yao, J, Lee, S, Tran, H, Xu, X, Liu, J, Celestino, J, Hajek, RA, Morgan, MB, Mohammad, M, Soliman, P, Shafer, A, Sood, AK, Bodurka, D, Fleming, ND, Grinsfelder, MO, Milojevic, L, Jazaeri AA, Mills, GB, Coleman, RL, Westin, SN. Combination Therapy with Copanlisib and Niraparib in Patients with Recurrent Endometrial and Ovarian Cancer (COPANIRA): Efficacy, Toxicity, and Translational Insights. Clinical Cancer Research, 2026. e-Pub 2026. PMID: 41528970.
2. How JA, Jazaeri AA. Photodynamic therapy: An alternative technique to cervical conization for cervical dysplasia. Med 6(12), 2025. e-Pub 2025. PMID: 41389709.
3. Ma, X, Hsu, YC, Asare, A, Zhang, K, Glassman, D, Handley, KF, Foster, KI, Sharma, K, Westin, SN, Jazaeri, AA, Fleming, N, Bhattacharya, PK, Jiang, X, Sood, AK, Shams, S. A pioneering artificial intelligence tool to predict treatment outcomes in ovarian cancer via diagnostic laparoscopy. Scientific reports 15(1), 2025. e-Pub 2025. PMID: 40281006.
4. Wolfe, CA, Povilaitis, SC, Keating, MF, Montgomery, A, Burt, BM, Jazaeri, AA, Eberlin, LS. Next generation MasSpec pen technology. International Journal of Mass Spectrometry 518, 2025. e-Pub 2025.
5. Hou, J, Ju, C-W, Egan, NA, Wei, Y, Wang, Y, Dang, M, Zhou, T, Shi, L, Zheng, N, Chen, S, Guerrero, AM, Liang, X, Wu, W, Akhtar, A, Dhiman, C, Burman, DR, Gerges, AE, Flores, MD, Li, H, Zhang, L-S, Kok, M, Mao, X, Wang, L, Feng, Q, Chen, Y, Lee, S, McGrail, DJ, Sahni, N, He, C, Jazaeri AA, Peng, W. Tumor Intrinsic METTL5 Modulates ATF4 Translation to Prevent T Cell-Induced Ferroptosis in Ovarian Cancer. Advanced Science 12(46), 2025. e-Pub 2025. PMID: 41042068.
6. Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA. PPP2R1A mutations portend improved survival after cancer immunotherapy. Nature 644(8076):537-546, 2025. e-Pub 2025. PMID: 40604275.
7. Knisely A, Dai Y, Barlow GL, Lee S, Lawson B, Clark H, Fellman B, Yuan Y, Lu W, Lubo Julio CI, Lazcano RN, Chelvanambi M, Melendez B, Singh B, Singh B, Wani K, Chen J, Yeh CC, Gao J, Barnes S, Shi O, Khan KB, Serrano AG, Gomez-Bolanos LI, Scalise CB, Cheung SK, Dutta P, Velichko S, ElNaggar AC, Liu MC, Wilke RN, How J, Ramondetta LM, Boruta DM, Richardson G, Shafer A, Westin SN, Sims T, Sood AK, Ramirez PT, Lazar AJ, Soliman PT, Lu K, Haymaker CL, Soto LMS, Wargo JA, Grisham R, Wucherpfennig KW, Wang L, Jazaeri AA. Surgical and blood-based minimal residual disease in patients with ovarian cancer after frontline therapy: Clinical outcomes and translational opportunities. Clinical Cancer Research 31(19):4122-4135, 2025. e-Pub 2025. PMID: 40748258.
8. Jazaeri AA, Moore KN, Jazaeri AA, Fang J, Patel I, Yuhas A, Innamarato P, Gilbert N, Dean JW, Damirchi B, Yglesias J, Qi R, Simpson-Abelson MR, Cammaart E, Hall SRR, Yin H. Feasibility of Manufacturing and Antitumor Activity of TIL for Advanced Endometrial Cancers. MDPI 26(15), 2025. e-Pub 2025. PMID: 40806287.
9. Jazaeri AA, Liao L, Zielinski RJ, Gomez JA, Basi AV, Seeley EH, Tan L, Bilecz AJ, Zhou W, Liu H, Wang C, Wu S, Qi Y, Miyamoto T, Severi F, Goldman AR, Gu S, Sood AK, Jazaeri AA, Drapkin R, Claiborne DT, Zhang N, Lorenzi PL, Burks JK, Lengyel E, Gottlieb E, Zhang R. Selective Alanine Transporter Utilization is a Therapeutic Vulnerability in ARID1A-Mutant Ovarian Cancer. Cancer Research 85(18):3471-3489, 2025. e-Pub 2025. PMID: 40658600.
10. Liu Y, Sinjab A, Min J, Han G, Paradiso F, Zhang Y, Wang R, Pei G, Dai Y, Liu Y, Cho KS, Dai E, Basi A, Burks JK, Rajapakshe KI, Chu Y, Jiang J, Zhang D, Yan X, Guerrero PA, Serrano A, Li M, Hwang TH, Futreal A, Ajani JA, Soto LMS, Jazaeri AA, Kadara H, Maitra A, Wang L. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer cell 43(5):905-924.e6, 2025. e-Pub 2025. PMID: 40154487.
11. Corvigno S, Yao J, Asare A, Zhao L, Celestino J, Hajek RA, Goette EAA, Rogers RT, Montoya RN, Song P, Zhang QC, Song X, Mohammad MM, Shaw KR, Zhang J, Lu KH, Jazaeri AA, Westin SN, Sood AK, Lee S. Longitudinal genomic profiling of chemotherapy-related CHIP variants in patients with ovarian cancer. Frontiers in Oncology 15, 2025. e-Pub 2025. PMID: 40365343.
12. Wermke M, Araujo D, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Alper Kursunel M, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee H-G, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nature medicine 31(7):2365-2374, 2025. e-Pub 2025. PMID: 40205198.
13. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
14. Knisely A, Ahmed J, Stephen B, Piha-Paul SA, Karp D, Zarifa A, Fu S, Hong DS, Rodon Ahnert J, Yap TA, Tsimberidou AM, Alshawa A, Dumbrava EE, Yang Y, Song J, Meric-Bernstam F, Jazaeri AA, Naing A. Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies. Cancer 130(3):400-409, 2024. e-Pub 2024. PMID: 37864520.
15. Eyada, M, Fellman, B, Patel, S, Michael, V, Soliman, PT, Sims, TT, How, JA, Jazaeri, AA, Fleming, N, Ramondetta, LM, Westin, SN. Gemcitabine plus cisplatin in recurrent ovarian, fallopian tube, and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
16. Eyada, M, Michael, V, Fellman, B, Patel, S, Soliman, PT, How, JA, Jazaeri, AA, Fleming, N, Sood, AK, Westin, SN, Sims, TT. Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer. Journal of Clinical Oncology 42(16), 2024. e-Pub 2024.
17. Vo D, Liu Y, Sood AK, Rezvani K, Jazaeri AA, Liu J. EGFR, HLA-G, CD70, c-MET, and NY-ESO1 as potential biomarkers in high grade epithelial ovarian carcinoma. Cancer Biomark. e-Pub 2023. PMID: 38250760.
18. Bernard L, How JA, Patel S, Yates MS, Jazaeri A. Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab. Gynecol Oncol 180:139-145. e-Pub 2023. PMID: 38091773.
19. Ing BI, Kuhl D, Glassman D, Johnson CA, Patel S, Jazaeri AA. Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer. Gynecol Oncol Rep 50:101296, 2023. e-Pub 2023. PMID: 37920829.
20. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer. e-Pub 2023. PMID: 38009662.
21. Jazaeri AA, Grisham R, Knisely A, Spranger S, Zamarin D, Hillman RT, Lawson BC, Burns KH, Lee S, Westin SN, Moiso E, Williams MJ, Bardhan NM, Pisanic T, Matulonis U, Weigelt B, Shih I, Konstantinopoulos PA, Gaillard S, Wang L, Aghajanian C, D'Andrea AD, Hammond P, Shah S, Wucherpfennig KW, Lu KH. Transforming ovarian cancer care by targeting minimal residual disease. Med 4(11):755-760, 2023. e-Pub 2023. PMID: 37951209.
22. Foster KI, Shaw KRM, Jin J, Westin SN, Yap TA, Glassman DM, Jazaeri AA, Rauh-Hain JA, Lee S, Fellman BM, Ju Z, Liu Y, Fleming ND, Sood AK. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129(11):1672-1680, 2023. e-Pub 2023. PMID: 36930815.
23. Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang L. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med 29(6):1550-1562, 2023. e-Pub 2023. PMID: 37248301.
24. Morris VK, Jazaeri A, Westin SN, Pettaway C, George S, Huey RW, Grinsfelder M, Shafer A, Johnson B, Vining D, Guo M, Fellman B, Frumovitz M. Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers. Oncologist. e-Pub 2023. PMID: 37104874.
25. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. e-Pub 2023. PMID: 36751659.
26. Westin SN, Fu S, Tsimberidou A, Piha-Paul S, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H, Hong DS, Pant S, Carter B, Jazaeri A, Gershenson D, Sood AK, Coleman RL, Shah J, Meric-Bernstam F, Naing A. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol 168:76-82, 2023. e-Pub 2023. PMID: 36423446.
27. Batman S, Rauh-Hain JA, Grinsfelder MO, Harrison R, Avila M, Cun H, How JA, Tandon N, Wang X, Hinchcliff E, Jazaeri AA, Schmeler KM. Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report. Case Rep Oncol 16(1):273-278, 2023. e-Pub 2023. PMID: 37123608.
28. Hinchcliff E, Rumpf J, Ratan R, Fleming ND, Jazaeri A, Fellman B, Meyer L, Soliman P. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma. Gynecol Oncol 167(3):490-495, 2022. e-Pub 2022. PMID: 36270831.
29. Mitra D, Farr M, Nagarajan P, Ho J, Bishop AJ, Jhingran A, Farooqi AS, Frumovitz M, Amaria RN, McQuade JL, Jazaeri AA, Guadagnolo BA. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression. Gynecol Oncol 167(3):483-489, 2022. e-Pub 2022. PMID: 36229264.
30. Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival. Gynecol Oncol. e-Pub 2022. PMID: 36137845.
31. Fix SM, Forget MA, Sakellariou-Thompson D, Wang Y, Griffiths TM, Lee M, Haymaker CL, Dominguez AL, Basar R, Reyes C, Kumar S, Meyer LA, Hwu P, Bernatchez C, Jazaeri AA. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. J Immunother Cancer 10(7), 2022. e-Pub 2022. PMID: 35882447.
32. Zhao L, Corvigno S, Ma S, Celestino J, Fleming ND, Hajek RA, Lankenau Ahumada A, Jennings NB, Thompson EJ, Tang H, Westin SN, Jazaeri AA, Zhang J, Futreal PA, Sood AK, Lee S. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer. Cancers (Basel) 14(15), 2022. e-Pub 2022. PMID: 35892848.
33. Hinchcliff E, Gunther J, Ponnie AE, Bednarski B, Onstad M, Shafer A, Frumovitz M, Jazaeri A, Urbauer D, Bodurka DC. A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. J Cancer Educ 37(3):615-620, 2022. e-Pub 2022. PMID: 32839894.
34. Nash AM, Jarvis MI, Aghlara-Fotovat S, Mukherjee S, Hernandez A, Hecht AD, Rios PD, Ghani S, Joshi I, Isa D, Cui Y, Nouraein S, Lee JZ, Xu C, Zhang DY, Sheth RA, Peng W, Oberholzer J, Igoshin OA, Jazaeri AA, Veiseh O. Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors. Sci Adv 8(9):eabm1032, 2022. e-Pub 2022. PMID: 35235346.
35. Colbert LE, El MB, Lynn EJ, Bronk J, Karpinets TV, Wu X, Chapman BV, Sims TT, Lin D, Kouzy R, Sammouri J, Biegert G, Delgado Medrano AY, Olvera A, Sastry KJ, Eifel PJ, Jhingran A, Lin L, Ramondetta LM, Futreal AP, Jazaeri AA, Schmeler KM, Yue J, Mitra A, Yoshida-Court K, Wargo JA, Solley TN, Hegde V, Nookala SS, Yanamandra AV, Dorta-Estremera S, Mathew G, Kavukuntla R, Papso C, Ahmed-Kaddar M, Kim M, Zhang J, Reuben A, Holliday EB, Minsky BD, Koong AC, Koay EJ, Das P, Taniguchi CM, Klopp A. Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. Cancer Immunol Res 10(2):259-271, 2022. e-Pub 2022. PMID: 35045973.
36. Ho J, Mattei J, Tetzlaff M, Williams MD, Davies MA, Diab A, Oliva ICG, McQuade J, Patel SP, Tawbi H, Wong MK, Fisher SB, Hanna E, Keung EZ, Ross M, Weiser R, Su SY, Frumovitz M, Meyer LA, Jazaeri A, Pettaway CA, Guadagnolo BA, Bishop AJ, Mitra D, Farooqi A, Bassett R, Faria S, Nagarajan P, Amaria RN. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma. Front Oncol 12:1001150, 2022. e-Pub 2022. PMID: 36324592.
37. Litwin RJ, Tam AL, Sheth RA, Yevich SM, Chan JL, Jazaeri AA, Halm JK, Gupta S, Huang SY. Safety and efficacy of percutaneous transabdominal and transesophageal decompression gastric catheters for palliation of malignant bowel obstruction. Abdom Radiol (NY) 46(9):4489-4498, 2021. e-Pub 2021. PMID: 33999283.
38. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB. Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clin Cancer Res. e-Pub 2021. PMID: 34518313.
39. Corsini EM, Mitchell KG, Zhou N, Bernatchez C, Forget MA, Haymaker CL, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Sepesi B, Swisher SG, Vaporciyan AA, Walsh GL, Amaria RN, Jazaeri AA, Antonoff MB. Pulmonary Resection for Tissue Harvest in Adoptive Tumor-Infiltrating Lymphocyte Therapy: Safety and Feasibility. J Surg Oncol 124(4):699-703, 2021. e-Pub 2021. PMID: 34057733.
40. Niu N, Shen W, Zhong Y, Bast RC, Jazaeri A, Sood AK, Liu J. Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas. Hum Pathol 113:20-27, 2021. e-Pub 2021. PMID: 33887301.
41. How JA, Patel S, Fellman B, Lu KH, Hwu P, Ramondetta LM, Westin SN, Fleming ND, Soliman PT, Jazaeri AA. Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. e-Pub 2021. PMID: 33958211.
42. Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33917869.
43. Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol. e-Pub 2021. PMID: 33838925.
44. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33668244.
45. How JA, Jazaeri AA, Soliman PT, Fleming ND, Gong J, Piha-Paul SA, Janku F, Stephen B, Naing A. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep 11(1):3667, 2021. e-Pub 2021. PMID: 33574401.
46. Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer 31(1):92-97, 2021. e-Pub 2021. PMID: 33154095.
47. How JA, Jazaeri A, Westin SN, Sood AK, Ramondetta LM, Xu M, Abonofal A, Karp DD, Subbiah V, Stephen B, Rodon JA, Yang F, Naing A. The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. Invest New Drugs. e-Pub 2021. PMID: 33415580.
48. El Alam MB, Sims TT, Kouzy R, Biegert GWG, JABI J, Karpinets TV, Yoshida-Court K, Wu X, Delgado-Medrano AY, Mezzari MP, Ajami NJ, Solley T, Ahmed-Kaddar M, Lin LL, Ramondetta L, Jazaeri A, Jhingran A, Eifel PJ, Schmeler KM, Wargo J, Klopp AH, Colbert LE. A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. PLoS One 16(3):e0247905, 2021. e-Pub 2021. PMID: 33662003.
49. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol 158(3):570-575, 2020. e-Pub 2020. PMID: 32534809.
50. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
51. How J, Patel A, Jazaeri AA. Immuno-oncology for Gynecologic Malignancies. Adv Exp Med Biol 1244:149-182, 2020. e-Pub 2020. PMID: 32301014.
52. Sakellariou-Thompson D, Forget MA, Hinchcliff E, Celestino J, Hwu P, Jazaeri AA, Haymaker C, Bernatchez C. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. e-Pub 2019. PMID: 31602489.
53. Shang S, Yang J, Jazaeri AA, Duval AJ, Tufan T, Lopes Fischer N, Benamar M, Guessous F, Lee I, Campbell RM, Ebert PJ, Abbas T, Landen CN, Difeo A, Scacheri PC, Adli M. Chemotherapy-induced distal enhancers drive transcriptional program to maintain the chemoresistant state in ovarian cancer. Cancer Res 79(18):4599-4611, 2019. e-Pub 2019. PMID: 31358529.
54. Sims TT, Colbert LE, Zheng J, Delgado Medrano AY, Hoffman KL, Ramondetta L, Jazaeri AA, Jhingran A, Schmeler KM, Daniel CR, Klopp A. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol Oncol. e-Pub 2019. PMID: 31500892.
55. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler MH, Mok SC, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri AA. Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. e-Pub 2019. PMID: 31515669.
56. Kazma J, Johnson C, Jain N, Gali VL, Young KH, Jazaeri AA. B-cell acute lymphoblastic leukemia/lymphoma in relapse presenting as a cervical mass: A case report and review of literature. Gynecol Oncol Rep 29:94-97, 2019. e-Pub 2019. PMID: 31467959.
57. Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunother Cancer 7(1):118, 2019. e-Pub 2019. PMID: 31053161.
58. Abu-Sbeih H, Ali FS, Wang X, Mallepally N, Chen E, Altan M, Bresalier RS, Charabaty A, Dadu R, Jazaeri AA, Lashner B, Wang Y. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 7(1):93, 2019. e-Pub 2019. PMID: 30940209.
59. Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer 6(7(1)):31, 2019. e-Pub 2019. PMID: 30728076.
60. Hinchcliff E, Hong D, Le H, Chisholm G, Iyer R, Naing A, Hwu P, Jazaeri A. Characteristics and Outcomes of Patients with Recurrent Ovarian Cancer Undergoing Early Phase Immune Checkpoint Inhibitor Clinical Trials. Gynecol Oncol 151(3):407-413, 2018. e-Pub 2018. PMID: 30366646.
61. Johnson C, AA J. Diagnosis and Management of Immune Checkpoint Inhibitor-related Toxicities in Ovarian Cancer: A Series of Case Vignettes. Clin Ther 40(3):389-394, 2018. e-Pub 2018. PMID: 29519715.
62. Roszik J, Ring KL, Wani KM, Lazar AJ, Yemelyanova AV, Soliman PT, Frumovitz M, Jazaeri AA. Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy. Front Immunol 9:2102, 2018. e-Pub 2018. PMID: 30283446.
63. Tetzlaff MT, AA J, Torres-Cabala CA, Korivi BR, Landon GA, Nagarajan P, Choksi A, Chen L, Uemura M, Aung PP, Diab A, Sharma P, Davies MA, Amaria R, Prieto VG, Curry JL. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy. Report of two patients. J Cutan Pathol 44(12):1080-1086, 2017. e-Pub 2017. PMID: 28901560.
64. Kumar P, Dillon LW, Shibata Y, AA J, Jones DR, Dutta A. Normal and Cancerous Tissues Release extrachromosomal circular DNA (eccDNA) into the Circulation. Mol Cancer Res 15(9):1197-1205, 2017. e-Pub 2017. PMID: 28550083.
65. Ring KL, Yemelyanova AV, Soliman PT, Frumovitz MM, AA J. Potential immunotherapy targets in recurrent cervical cancer. Gynecol Oncol 145(3):462-468, 2017. e-Pub 2017. PMID: 28233576.
66. Gorski JW, Taylor JS, Zhang J, Liu J, AA J. Hormonal Based Treatment of Ovarian Anaplastic Ependymoma with Anastrozole. Gynecol Oncol Rep 20:93-96, 2017. e-Pub 2017. PMID: 28393092.
67. Qin Y, Ekmekcioglu S, Forget MA, Szekvolgyi L, Hwu P, Grimm EA, AA J, Roszik J. Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol 8:689, 2017. e-Pub 2017. PMID: 28670312.
68. Yuan Y, Guo B, Munsell M, Lu K, A J. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Stat Med 35(22):3892-906, 2016. e-Pub 2016. PMID: 27112322.
69. Ring KL, Pakish J, AA J. Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer J 22(2):101-107, 2016. e-Pub 2016. PMID: 27111905.
70. Varadaraj A, Patel P, Serrao A, Bandyopadhay T, Lee NY, AA J, Huang Z, Murphy SK, Mythreye K. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia. Neoplasia 17(11):826-38, 2015. e-Pub 2015. PMID: 26678910.
71. Pires ES, D'Souza RS, Needham MA, Herr AK, AA J, Li H, Stoler MH, Anderson-Knapp KL, Thomas T, Mandal A, Gougeon A, Flickinger CJ, Bruns DE, Pollok BA, Herr JC. Membrane associated cancer-oocyte neoantigen SAS1B/ovastacin is a candidate immunotherapeutic target for uterine tumors. Oncotarget 6(30):30194-211, 2015. e-Pub 2015. PMID: 26327203.
72. Scalici JM, Harrer C, Allen A, A J, Atkins KA, McLachlan KR, Slack-Davis JK. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin. Gynecol Oncol 132(2):455-61, 2014. e-Pub 2014. PMID: 24378876.
73. Jividen K, Movassagh MJ, A J, Li H. Two methods for establishing primary human endometrial stromal cells from hysterectomy specimens. J Vis Exp(87), 2014. e-Pub 2014. PMID: 24894444.
74. Qiao Y, Quinlan AR, AA J, Verhaak RG, Wheeler DA, Marth GT. Subclone Seeker: a computational framework for reconstructing tumor clone structure for cancer variant interpretation and prioritization. Genome Biol 15(8):443, 2014. e-Pub 2014. PMID: 25160522.
75. AA J, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 12(10):1958-67, 2013. e-Pub 2013. PMID: 23939375.
76. Aprelikova O, Palla J, Hibler B, Yu X, Greer YE, Yi M, Stephens R, Maxwell GL, A J, Risinger JI, Rubin JS, Niederhuber J. Silencing of miR-148a in cancer-associated fibroblasts results in WNT10B-mediated stimulation of tumor cell motility. Oncogene 32(27):3246-53, 2013. e-Pub 2013. PMID: 22890324.
77. Courtney-Brooks M, Scalici J, Henretta MS, Modesitt SC, AA J, Cantrell LA, Duska LR. Vulvar necrotizing soft tissue infection: A review of a multi-disciplinary surgical emergency and management in the modern era. Gynecol Oncol Case Rep 5:6-9, 2013. e-Pub 2013. PMID: 24371682.
78. Courtney-Brooks M, Tellawi AR, Scalici J, Duska LR, Jazaeri AA, Modesitt SC, Cantrell LA. Frailty: an outcome predictor for elderly gynecologic oncology patients. Gynecol Oncol 126(1):20-4, 2012. e-Pub 2012. PMID: 22522190.
79. AA J, Bryant JL, Park H, Li H, Dahiya N, Stoler MH, Ferriss JS, Dutta A. Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia 13(10):899-911, 2011. e-Pub 2011. PMID: 22028616.
80. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, AA J, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecol Oncol 121(1):2-7, 2011. e-Pub 2011. PMID: 21269667.
81. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Modesitt SC, AA J. Appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Obstet Gynecol 116(6):1348-53, 2010. e-Pub 2010. PMID: 21099601.
82. Aprelikova O, Yu X, Palla J, Wei BR, John S, Yi M, Stephens R, Simpson RM, Risinger JI, A J, Niederhuber J. The role of miR-31 and its target gene SATB2 in cancer-associated fibroblasts. Cell Cycle 9(21):4387-98, 2010. e-Pub 2010. PMID: 20980827.
83. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A. Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol 118(2):189-95, 2010. e-Pub 2010. PMID: 20462630.
84. Greene DP, Ferriss JS, AA J. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother Pharmacol 66(2):265-7, 2010. e-Pub 2010. PMID: 19844714.
85. Terai K, Abbas T, AA J, Dutta A. CRL4(Cdt2) E3 ubiquitin ligase monoubiquitinates PCNA to promote translesion DNA synthesis. Mol Cell 37(1):143-9, 2010. e-Pub 2010. PMID: 20129063.
86. Ferriss JS, Atkins KA, Lachance JA, Modesitt SC, AA J. Temozolomide in advanced and recurrent uterine leiomyosarcoma and correlation with o6-methylguanine DNA methyltransferase expression: a case series. Int J Gynecol Cancer 20(1):120-5, 2010. e-Pub 2010. PMID: 20130512.
87. Jazaeri AA, Slack-Davis JK. The promise of antiangiogenic therapy for ovarian cancer. Cancer Biol Ther 8(23):2273-4, 2009. e-Pub 2009. PMID: 19907207.
88. Bland AE, Stone R, Heuser C, Shu J, A J, Shutter J, Atkins K, Rice L. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 19(2):261-5, 2009. e-Pub 2009. PMID: 19396006.
89. Lachance JA, Shutter J, Atkins KA, Stoler MH, Rice LW, AA J. Utilization of a uniform grading system for interpreting serous ovarian cancer. Am J Obstet Gynecol 199(2):189.e1-6, 2008. e-Pub 2008. PMID: 18501326.
90. Darus CJ, Callahan MB, Nguyen QN, Pastore LM, Schneider BF, Rice LW, AA J. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. Int J Gynecol Cancer 18(4):730-5, 2008. e-Pub 2008. PMID: 17949426.
91. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, AA J. A cost comparison of two strategies for treating stage IB2 cervical cancer. Int J Gynecol Cancer 18(2):274-8, 2008. e-Pub 2008. PMID: 18334009.
92. Lachance JA, Stukenborg GJ, Schneider BF, Rice LW, AA J. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. Gynecol Oncol 108(1):77-83, 2008. e-Pub 2008. PMID: 17936341.
93. Callahan MB, Lachance JA, Stone RL, Kelsey J, Rice LW, AA J. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 197(2):199.e1-4; discussion 199.e4-5, 2007. e-Pub 2007. PMID: 17689649.
94. Young JL, Jazaeri AA, Lachance JA, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. Am J Obstet Gynecol 197(2):195.e1-7; discussion 195.e7-8, 2007. e-Pub 2007. PMID: 17689647.
95. Everett EN, French AE, Stone RL, Pastore LM, AA J, Andersen WA, Taylor PT. Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer. Am J Obstet Gynecol 195(2):568-74; discussion 574-6, 2006. e-Pub 2006. PMID: 16890558.
96. Rice LW, Stone RL, Xu M, Galgano M, Stoler MH, Everett EN, AA J. Biologic targets for therapeutic intervention in endometrioid endometrial adenocarcinoma and malignant mixed müllerian tumors. Am J Obstet Gynecol 194(4):1119-26; discussion 1126-8, 2006. e-Pub 2006. PMID: 16580307.
97. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC, Boyd J. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 11(17):6300-10, 2005. e-Pub 2005. PMID: 16144934.
98. Jazaeri AA, Chandramouli GV, Aprelikova O, Nuber UA, Sotiriou C, Liu ET, Ropers HH, Yee CJ, Boyd J, Barrett JC. BRCA1-mediated repression of select X chromosome genes. J Transl Med 2(1):32, 2004. e-Pub 2004. PMID: 15383145.
99. Zorn KK, Jazaeri AA, Awtrey CS, Gardner GJ, Mok SC, Boyd J, Birrer MJ. Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9(13):4811-8, 2003. e-Pub 2003. PMID: 14581352.
100. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, A J, Martiat P, Fox SB, Harris AL, Liu ET. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 100(18):10393-8, 2003. e-Pub 2003. PMID: 12917485.
101. Jazaeri AA, Lu K, Schmandt R, Harris CP, Rao PH, Sotiriou C, Chandramouli GV, Gershenson DM, Liu ET. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol Carcinog 36(2):53-9, 2003. e-Pub 2003. PMID: 12557260.
102. Risinger JI, Maxwell GL, Chandramouli GV, A J, Aprelikova O, Patterson T, Berchuck A, Barrett JC. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res 63(1):6-11, 2003. e-Pub 2003. PMID: 12517768.
103. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 94(13):990-1000, 2002. e-Pub 2002. PMID: 12096084.
104. Sotiriou C, Khanna C, AA J, Petersen D, Liu ET. Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn 4(1):30-6, 2002. e-Pub 2002. PMID: 11826185.
105. Sotiriou C, Powles TJ, Dowsett M, AA J, Feldman AL, Assersohn L, Gadisetti C, Libutti SK, Liu ET. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 4(3):R3, 2002. e-Pub 2002. PMID: 12052255.
106. Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20(47):6965-9, 2001. e-Pub 2001. PMID: 11687977.
107. Foley EF, Jazaeri A, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 60(2):245-8, 2000. e-Pub 2000. PMID: 10667568.
108. Jazaeri O, Shupnik MA, Jazaeri AA, Rice LW. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol 74(1):38-47, 1999. e-Pub 1999. PMID: 10385549.
109. Rice LW, Jazaeri AA, Shupnik MA. Estrogen receptor mRNA splice variants in pre- and postmenopausal human endometrium and endometrial carcinoma. Gynecol Oncol 65(1):149-57, 1997. e-Pub 1997. PMID: 9103405.
110. Philpot BD, AA J, Brunjes PC. The development of serotonergic projections to the olfactory bulb of Monodelphis domestica (the grey, short-tailed opossum). Brain Res Dev Brain Res 77(2):265-70, 1994. e-Pub 1994. PMID: 8174233.
111. Brunjes PC, A J, Sutherland MJ. Olfactory bulb organization and development in Monodelphis domestica (grey short-tailed opossum). J Comp Neurol 320(4):544-54, 1992. e-Pub 1992. PMID: 1378458.

Invited Articles

1. Bae-Jump V, AA J. Summary of the 2012 American Association for Cancer Research (AACR) Annual Meeting 126(2):174-5, 2012. e-Pub 2012.

Review Articles

1. Ring, K, Mills, AM, Howitt, BE, Grisham, RN, Euscher, ED, Kim, HS, Klopp, AH, Kolin, DL, McCluggage, WG, Mirkovic, J, Park, K, Aoun, E, Awujo, C, Son, J, Mok, S, Ferri-Borgogno, S, Hong, DS, Hoang, L, Jazaeri, AA, How, JA, Lu, KH. Mesonephric-like adenocarcinoma of the female genital tract. Gynecologic oncology 197:57-65, 2025. e-Pub 2025. PMID: 40279981.
2. Fleming, N, Wolfe, CA, Keating, MF, Sans, M, Rangel, KM, Sunny, C, Westin, SN, Jazaeri, AA, Soliman, PT, Taylor, JS, Hillman, RT, How, JA, Lawson, BC, Sood, AK, Eberlin, LS. Feasibility of using the handheld MasSpec pen technology for intraoperative identification of ovarian cancer during tumor reductive surgery. Journal of Clinical Oncology 42:5573, 2024. e-Pub 2024.
3. Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, Hong DS. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecol Oncol 165(3):664-670, 2022. e-Pub 2022. PMID: 35400527.
4. Fix SM, Jazaeri AA, Hwu P. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discov 11(3):560-574, 2021. e-Pub 2021. PMID: 33563662.
5. How JA, Patel A, Jazaeri AA. Immuno-Oncology for Gynecologic Malignancies. Adv Exp Med Biol 1342:193-232, 2021. e-Pub 2021. PMID: 34972966.
6. Santin AD, Deng W, Frumovitz M, Buza N, Bellone S, Huh W, Khleif S, Lankes HA, Ratner ES, O'Cearbhaill RE, Jazaeri AA, Birrer M. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol 157(1):161-166, 2020. e-Pub 2020. PMID: 31924334.
7. Roelands J, Garand M, Hinchcliff E, Ma Y, Shah P, Toufiq M, Alfaki M, Hendrickx W, Boughorbel S, Rinchai D, Jazaeri A, Bedognetti D, Chaussabel D. Long-Chain Acyl-CoA Synthetase 1 Role in Sepsis and Immunity: Perspectives From a Parallel Review of Public Transcriptome Datasets and of the Literature. Front Immunol 10:2410, 2019. e-Pub 2019. PMID: 31681299.
8. Jazaeri A, Coleman RL, Sood AK, Frumovitz MM, Soliman PT, Shafer A, Cutrera JJ, Klinger M, Sharafi SE, Johnson CAL, Villanueva VF, Hinchcliff EM, Dickens A, Cain KE, Anderson JE, Lu KH, Westin SN. A Practical Guide for the Safe Implementation of Early Phase Drug Development and Immunotherapy Program in Gynecologic Oncology Practice. Gynecol Oncol 151(2):374-380, 2018. e-Pub 2018. PMID: 30213435.
9. Pakish JB, AA J. Immunotherapy in Gynecologic Cancers: Are We There Yet?. Curr Treat Options Oncol 18(10):59, 2017. e-Pub 2017. PMID: 28840453.
10. AA J. Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease. Mol Oncol 3(2):151-6, 2009. e-Pub 2009. PMID: 19383376.
11. Young JL, Jazaeri AA, Darus CJ, Modesitt SC. Cyclooxygenase-2 in cervical neoplasia: a review. Gynecol Oncol 109(1):140-5, 2008. e-Pub 2008. PMID: 18275990.
12. Modesitt SC, AA J. Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics. Expert Opin Pharmacother 8(14):2293-305, 2007. e-Pub 2007. PMID: 17927484.

Other Articles

1. Dai, Y, Knisely, A, Yano, M, Dang, M, Hinchcliff, EM, Lee, S, Welp, A, Chelvanambi, M, Lastrapes, M, Liu, H, Yuan, Z, Wang, C, Nie, H, Jean, S, Montaner, LJ, Hou, J, Patel, A, Patel, S, Fellman, B, Yuan, Y, Sun, B, Pandurengan, RK, Cuentas, EP, Celestino, J, Liu, Y, Liu, J, Hillman, RT, Westin, SN, Sood, AK, Soliman, PT, Shafer, A, Meyer, LA, Gershenson, DM, Vining, D, Ganeshan, DM, Lu, KH, Wargo, J, Peng, W, Zhang, R, Wang, L, Jazaeri, AA Author Correction. Nature 645(8082):E10, 2025. PMID: 40913056.
2. Wermke, M, Araujo, DM, Chatterjee, M, Tsimberidou, AM, Holderried, TA, Jazaeri, AA, Reshef, R, Bokemeyer, C, Alsdorf, WH, Wetzko, K, Brossart, P, Aslan, K, Backert, L, Bunk, S, Fritsche, J, Gulde, S, Hengler, S, Hilf, N, Hossain, MB, Hukelmann, J, Kalra, M, Krishna, D, Kursunel, MA, Maurer, D, Mayer-Mokler, A, Mendrzyk, R, Mohamed, A, Pozo, K, Satelli, A, Letizia, M, Schuster, H, Schoor, O, Wagner, C, Rammensee, HG, Reinhardt, C, Singh-Jasuja, H, Walter, S, Weinschenk, T, Luke, JJ, Britten, CM Author Correction. Nature medicine 31(7):2453, 2025. PMID: 40301562.

Editorials

1. Sims TT, Jazaeri AA. Recruiting for diversity in immunotherapy trials for breast and gynecologic cancers: moving beyond under-representation. Int J Gynecol Cancer 31(11):1408-1409, 2021. PMID: 34551893.
2. Hinchcliff E, Jazaeri AA. Sunset, or dawn of a new age for ovarian cancer vaccine therapy?. Gynecol Oncol 155(3):387-388, 2019. PMID: 31812214.
3. Jazaeri AA. Immunotherapy in ovarian cancer: where are we now, and where are we going?. Clin Adv Hematol Oncol 15(11):851-853, 2017. PMID: 29200418.
4. Nelson BH, AA J. Immunotherapy for gynecological cancers: opportunities abound. Gynecol Oncol 145(3):411-412, 2017. PMID: 28552394.
5. Zamarin D, AA J. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecol Oncol 141(1):86-94, 2016. PMID: 27016233.

Abstracts

1. Knisely, A, Jazaeri, AA. Prognostic implications of minimal residual disease detection by second look laparoscopy and circulating tumor DNA in patients with ovarian cancer after frontline therapy. SGO Annual Meeting 2024, 2024. e-Pub 2024.
2. How JA, Bolonesi R, Jazaeri A. Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
3. Santosh K, Powell R, Nguyen N, Sobieski M, Stephan C, Bahl A, Yap T, Jazaeri A, Westin S, Sood A. Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
4. Knisely, A, Jazaeri A. Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
5. Westin SN, Dansky Ullmann C, Sims T, Jazaeri A. A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube. ASCO Annual Meeting 2023, 2023. e-Pub 2023.
6. Jazaeri AA, Nitecki. Initial clinicopathologic and molecular characterization of minimal residual disease detected by second look laparoscopy after completion of frontline surgery and chemotherapy in patients with advanced stage ovarian cancer. AACR Annual Meeting 2022, 2022. e-Pub 2022.
7. Morris V, Jazaeri AA, Westin SN, Pettaway C, George S, Huey R, Onstad M, Tu SM, Wang J, Shafer A, Johnson B, Xiao L, Vining D, Guo M, Yuan Y, Frumovitz M. Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers. 2021 ASCO Annual Meeting - Poster Session: Developmental Therapeutics—Immunotherapy, 2021. e-Pub 2021.
8. Jazaeri AA. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. Society of Gynecologic Oncology Annual Meeting 2021, 2021. e-Pub 2021.
9. How JA, Dang M, Euscher E, Yates M, Peng W, Divyesh Patel S, Lu KH, Hwu P, Wang, L, Jazaeri AA. The impact of the tumor immune microenvironment on response to pembrolizumab in patients with microsatellite instability-high endometrial cancer. AACR Virtual Special Conference - Endometrial Cancer: New Biology Driving Research and Treatment, 2020. e-Pub 2020.
10. Frumovitz M, Westin SN, Yap T, Rodon JA, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab for high-grade neuroendocrine tumors of the cervix and vulva. Society of Gynecologic Oncology Annual Meeting, 2020. e-Pub 2020.
11. Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Jazaeri AA, Liu J, Burks JK, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer. Society of Gynecologic Oncology Annual Meeting, 2020. e-Pub 2020.
12. Cun H, Hinchcliff EM, Zhu Y, Ferri-Borgogno S, Cheng R, Burks JK, Wong STC, Jazaeri AA, Mok SC. Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in high-grade serous ovarian carcinoma. Society of Gynecologic Oncology Annual Meeting, 2020. e-Pub 2020.
13. How JA, Timms KM, Jazaeri AA, Lu KH, Yates MS. Characterization of homologous recombination deficiency in uncommon epithelial ovarian cancer subtypes. Society of Gynecologic Oncology Annual Meeting, 2020. e-Pub 2020.
14. Moufarrij SM, Sood AK, Westin SN, Meyer L, Fellman B, Soliman PT, Jazaeri AA, Coleman RL, Rauh-Hain JA, Lu KH, Fleming ND. Socioeconomic barriers to care in advanced ovarian cancer: Does a 'one size fits all' model exist when treated at a NCI-designated tertiary cancer center?. Society of Gynecologic Oncology Annual Meeting, 2020. e-Pub 2020.
15. Hinchcliff E, Roszik J, Yemelyanova A, Yates M, Hwu P, Jazaeri AA. Immune response changes in HPV-related vulvar malignancy. Society of Gynecologic Oncology Annual Meeting, 2019. e-Pub 2019.
16. Hinchcliff E, Paquette C, Roszik J, Kelting S, Stoler M, Mok S, Yeung TL, Zhang Q, Yates M, Peng W, Hwu P, Jazaeri AA. Lymphocyte-specific protein tyrosine kinase expression predicts survival in ovarian high-grade serous carcinoma. Society of Gynecologic Oncology Annual Meeting, 2019. e-Pub 2019.
17. Colbert L, Medrano AD, Mikkelson M, Previs R, Eifel P, Jhingran A, Ramondetta L, Futreal P, Jazaeri A, Frumovitz M, Schmeler K, Hillman R, Matthew G, Hutchinson D, Ajami N, Stecklein S, Okhuysen P, Petrosino J, Hahn S, Klopp A. Clonal Expansion of Antigen Specific T-cells During Radiation Therapy for HPV Associated Cervical Cancers is Regulated by the Vaginal Microbiome. Proceedings of the 2018 Annual American Society for Radiation Oncology (ASTRO) Meeting, 2018. e-Pub 2018.
18. Jazaeri AA. A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma. Proceedings of the 2018 Annual American Society of Clinical Oncology Annual Meeting, 2018. e-Pub 2018.
19. Apostolia M, Tsimberidou A, Borje S, Andersson M, Stewart C, Hong M, Schoor O, Satelli A, Fritsche J, Bulliard Y, Mohamed A, Jazaeri AA, Hwu P, Yee C, Weinschenk T, Reinhardt C, Walter S, Singh H. Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog IMA101) in patients with relapsed and/or refractory solid cancers. ASCO-SITC, 2018. e-Pub 2018.
20. Colbert L, Dorta-Estremera S, Previs R, Eifel P, Jhingran A, Ramondetta L, Hahn S, Welsh J, Jazaeri A, Frumovitz M, Sastry J, Klopp A. Effect of chemoradiation for cervical cancer on transient decrease and variable expansion in T-cell infiltrate and diversity of T-cell repertoire. Proceedings of the 2017 Annual American Society of Clinical Oncology, 2017. e-Pub 2017.
21. Odunsi K, Cristea M, Dorigo O, Jazaeri AA, Slomovitz B, Chagin K, Van Winkle E, Kari G, Iyengar M, Norry E, Pandite L, Amado R. A phase I/IIa, open label, clinical trial evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 in patients with recurrent or treatment refractory ovarian cancer. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
22. Roszik J, Qin Y, Ekmekcioglu S, Forget M, Hwu P, Grimm E, Jazaeri AA. The neoantigen landscape and immune regulators in cervical cancer. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
23. Naing A, Lopez-Berestein G, Fu S, Tsimberidou A, Pant S, Piha-Paul S, Janku F, Hong D, Sulovic S, Meng X, Jazaeri AA, Ng C, Karp D, Subbiah V, Meric-Bernstam F, Mitra R, Wu S, Sood A, Coleman R. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial. Proceedings of the 2017 Annual American Society of Clinical Oncology Annual Meeting, 2017. e-Pub 2017.
24. Vankayalapati H, Yerramreddy V, ZHou J, Handler J, Appalaneni R, Kancherla R, Wu R, Takemori H, Whitehurst A, Jazaeri AA, Coleman R, Lu Z, Bast R. Discovery of ARN-3261 as a potent, selective, orally available SIK2 inhibitor for treating ovarian, endometrial, primary peritoneal, fallopian tube, and triple negative breast cancers. Proceedings of the 2017 American Association for Cancer Research Annual Meeting, 2017. e-Pub 2017.
25. Khawaja M, Nick A, Jazaeri AA, Madhusudanannair V, Ng C, Janku F, Piha-Paul S, Soliman P, Fu S, Hong D, Karp D, Subbiah V, Tsimberidou A, Coleman R, Sood A, Meric-Bernstam F, Lu K, Naing A. Dose Expansion Study of Temsirolimus in Combination with Metformin in Patients with Advanced Endometrial Cancers. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016. e-Pub 2016.
26. Pakish J, Zhang Q, Jazaeri AA, Celestino J, Kwan S, Mok S, Yates M, Lu K. Endometrial cancer subtypes and immunotherapy: Is the immune microenvironment different in microsatellite instable endometrial cancers?. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016. e-Pub 2016.
27. Naing A, Lopez G, Fu S, Tsimberidou A, Kato SM, Piha-Paul S, Janku F, Hong D, Nick A, Jazaeri AA, Ng C, Karp D, Subbiah V, Meric-Bernstam F, Sood A, Coleman R. EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A Phase I clinical trial. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016. e-Pub 2016.
28. Jazaeri AA, Paquette C, Kelting S, Stoler M, Zhang Q, Yates M, Creasy C, Bernatchez C. Prognostic and Biologic Significance of High LCK Expression in Ovarian Cancer. 52nd Annual Meeting of the American Society of Clinical Gynecology, 2016. e-Pub 2016.
29. Jazaeri AA, Paquette, C, Kelting, SStoler, M, Zhang, Q, Yates, M, Creasy, Bernatchez C, C, HwuP. Prognostic and Biologic Significance of High LCK Expression in Ovarian Cancer. 30th Annual Meeting of the Society of Immunotherapy of Cancer, 2015. e-Pub 2015.
30. Sakellariou-Thompson D, Haymaker C, Forget M, Jazaeri AA, Hwu P, Bernatchez C. Preclinical development of tumor infiltrating lymphocyte therapy for ovarian cancer. 30th Annual Meeting of the Society of Immunotherapy of Cancer, 2015. e-Pub 2015.
31. Barrett MR, Quinlan AR, Johnson CA, Moskaluk CA, Jazaeri AA. Identification of somatic mutations in uterine leiomyosarcomas. Annual Meeting of the Mid-Atlantic Gynecologic Oncologic Society, 2013. e-Pub 2013.
32. Pires ES, Li H, Stoler MA, Jazaeri AA, Bruns D, Herr JC. Uterine tumor cell growth arrest using an immunotoxin directed to the oocyte-associated cancer cell surface target SAS1B. Meeting of the American Society of Reproductive Immunology, 2013. e-Pub 2013.
33. Casarez EV, Gray L, Jazaeri AA, Slack-Davis JK. Inhibition of T-type calcium channels sensitizes ovarian cancer cell growth and metastasis to platinum-based chemotherapy. 104th Annual Meeting of American Association for Cancer Research, 2013. e-Pub 2013.
34. Jazaeri AA, Shibata E, Park JH, Bryant JL, Conaway MR, Modesitt, SC, Milhollen M, Smith P, Berger A, Dutta A. Overcoming platinum resistance in ovarian cancer using the novel compound MLN4924. 104th Annual Meeting of American Association for Cancer Research, 2013. e-Pub 2013.
35. Courtney-Brooks M, Modesitt SC, Jazaeri AA, Duska LR. At the end of life: Optimizing quality of care for women dying of cervical cancer. 44th Annual Meeting of Society for Gynecologic Oncologists, 2013. e-Pub 2013.
36. Dahiya N, Aprelikova O, Neiderhuber J, Bryant, JL, Jazaeri AA. Comparison of cisplatin induced changes in serous ovarian cancer and normal fallopian tube cells. 103rd Annual Meeting of American Association for Cancer Research, 2012. e-Pub 2012.
37. Ring K, Abbas T, Dutta A, Jazaeri AA. Oncogenic role of cullin 4 E3 ubiquitin ligase (CRL4-CDT2) in epithelial ovarian cancer. 102nd Annual Meeting of American Association for Cancer Research, 2011. e-Pub 2011.
38. Scalici J, Harrer C, Atkins K, Jazaeri AA, Duska L, Slack-Davis J. Clinical significance of vascular cell adhesion molecule 1 in the ovarian cancer microenvironment. 42nd Annual Meeting of Society for Gynecologic Oncologists, 2011. e-Pub 2011.
39. Jazaeri AA, Bryant JL, Park H, Ferriss JS, Li H, Dutta A. Modeling of early events in serous carcinogenesis: Molecular prerequisites for transformation of fallopian tube epithelial cells. 42nd Annual Meeting of Society for Gynecologic Oncologists, 2011. e-Pub 2011.
40. Aprelikova O, Palla J, John S, Yi M, Stephens R, Risinger JI, Jazaeri AA, Niederhuber J, Yu X. SatB2, targeted by miR31, is a modulator in cancer microenvironment. 101st Annual Meeting of American Association for Cancer Research, 2010. e-Pub 2010.
41. Palla J, Aprelikova O, Yu X, John S, Yi M, Stevens R, Risinger JI, Jazaeri AA, Niederhuber J. Activation of WNT pathway in endometrial cancer stromal fibroblasts. 101st Annual Meeting of American Association for Cancer Research, 2010. e-Pub 2010.
42. Jazaeri AA, Ferriss JS, Machida Y, Bryant JL, Dalton MS, Dutta A. Expression and function of EVI1 and EVI1s (Δ324) in ovarian cancer. 101st Annual Meeting of American Association for Cancer Research, 2010. e-Pub 2010.
43. Ferriss JS, Dalton MS, Bryant JL, Modesitt SC, Jazaeri AA. In-vitro model for serous carcinomas arising in the distal fallopian tube. 41st Annual Meeting of Society for Gynecologic Oncologists, 2010. e-Pub 2010.
44. King ER, Jazaeri AA. Counseling patients with recurrent/progressive epithelial ovarian cancer: What is the true efficacy of advanced line chemotherapeutic regimens?. 40th Annual Meeting of Society for Gynecologic Oncologists, 2009. e-Pub 2009.
45. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Andersen WA, Modesitt SC, Jazaeri AA. Appendectomy in the setting of a pelvic mass: are ovarian frozen pathology and gross appearance of the appendix predictive of coexisting appendiceal pathology?. 40th Annual Meeting of Society for Gynecologic Oncologists, 2009. e-Pub 2009.
46. Timofeev J, Galgano MT, Stoler MH, Lachance, JA, Andersen WA, Modesitt SC, Jazaeri AA. Prevalence of appendiceal pathology at the time of oophorectomy for ovarian neoplasms. Annual Meeting of the South Atlantic Association of Obstetricians and Gynecologists, 2009. e-Pub 2009.
47. Timofeev J, Galgano MT, Stoler MH, Lachance JA, Andersen WA, Modesitt SC, Jazaeri AA. Appendectomy in the setting of a pelvic mass: are ovarian frozen pathology and gross appearance of the appendix predictive of coexisting appendiceal pathology?. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2008. e-Pub 2008.
48. King ER, Jazaeri A. Counseling patients with recurrent/progressive epithelial ovarian cancer: What is the true efficacy of advanced line chemotherapeutic regimens?. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2008. e-Pub 2008.
49. Ferriss JS, Machida Y, Dalton MS, Bryant JL, Dutta A, Jazaeri AA. EVI1 isoforms exhibit different effects on growth and apoptosis in ovarian cancer. 39th Annual Meeting of Society for Gynecologic Oncologists, 2008. e-Pub 2008.
50. Lachance JA, Stukenborg GJ, Choudhri A, Sarti M, Cassidy MK, Jazaeri AA. A multivariable analysis model for pre-operative prediction of ovarian cancer in adnexal masses. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2007. e-Pub 2007.
51. Ferriss JS, Lachance JA, Modesitt SC, Jazaeri AA. Treatment of advanced & recurrent leiomyosarcoma with temozolomide. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2007. e-Pub 2007.
52. Stone R, Rice LW, Dunlap-Brown M, Jazaeri AA. In-vitro and in-vivo responses of Ishikawa endometrial cancer cells to an Akt inhibitor. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
53. Bland AE, Stone RL, Heuser CC, Jazaeri AA, Shu, J, Shutter J, Atkins K, Rice LW. A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
54. Lachance JA, Schneider BJ, Rice LW, Stukenborg GJ, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of stage I endometrial adenocarcinoma. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
55. Lachance JA, Callahan MB, Stone RL, Kelsey J, Rice LW, Jazaeri AA. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
56. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost comparison of two strategies for treating stage IB2 cervical cancer. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
57. Young JL, Jazaeri AA, Lachance J, Stoler MH, Irvin WP, Rice LW, Andersen WA, Modesitt SC. Cervical adenocarcinoma in situ: the predictive value of conization margin status. 38th Annual Meeting of Society for Gynecologic Oncologists, 2007. e-Pub 2007.
58. Lachance JA, Darus CJ, Stukenborg GJ, Schneider BF, Rice LW, Jazaeri AA. A cost comparison of two strategies for treating stage IB2 cervical cancer. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2006. e-Pub 2006.
59. Callahan MB, Stone RL, Lachance JA, Kelsey J, Rice LW, Jazaeri AA. Cisplatin rechallenge without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2006. e-Pub 2006.
60. Lachance JA, Stukenborg GJ, Schneider BJ, Rice LW, Jazaeri AA. A cost-effective analysis of adjuvant therapies for the treatment of Stage I endometrial adenocarcinoma. Annual Meeting of the Mid-Atlantic Gynecologic Oncology Society, 2006. e-Pub 2006.
61. Darus CJ, Callahan MB, Nguyen Q, Pastore LM, Schneider BF, Rice LW, Jazaeri AA. Chemoradiation with and without adjuvant extrafascial hysterectomy for IB2 cervical carcinoma. 37th Annual Meeting of Society for Gynecologic Oncologists, 2006. e-Pub 2006.
62. Dalton MS, Bryant JL, Jazaeri AA. Molecular beacons for detection of RNA in ovarian cancer cells. Virginia Cancer Research Seminar, 2005. e-Pub 2005.
63. Darus CJ, Atkins KA, Slack-Davis JA, Xu M, Dalton MS, Rice LW, Jazaeri AA. Expression and phosphorylation of focal adhesion kinase in endometrial adenocarcinoma and malignant mixed mullerian tumors. Annual Meeting, Society for Gynecologic Investigation, 2005. e-Pub 2005.
64. Jazaeri AA, Awtrey C, Gadisetti C, Sotiriou C, Yee C, Chuang E, Khan J, Zorn KK, Birrer M, Barret JC, Boyd J. Molecular changes associated with response to chemotherapy in primary epithelial ovarian cancers. Joint Annual Meeting of the Felix Rutledge Society and the Western Association of Gynecologic Oncologists, 2004. e-Pub 2004.
65. Jazaeri AA, Awtrey C, Gadisetti C, Sotiriou C, Yee C, Khan J, Boyd, J, Barret JC. Molecular changes associated with response to chemotherapy in primary epithelial ovarian cancers. 34th Annual Meeting of the Society of Gynecologic Oncologists, 2003. e-Pub 2003.
66. Jazaeri AA, Yee C, Sotiriou C, Brantley K, Boyd J, Liu ET. Gene expression profiles of BRCA-linked and sporadic ovarian cancers. 33rd Annual Meeting of the Society of Gynecologic Oncologists, 2002. e-Pub 2002.
67. Mihm LL, Jazaeri AA, Brumfield JA, Quick VA, Connors AF, Finnerty JJ. The accuracy of endometrial biopsy and saline sonohysterography in determining the etiology of abnormal uterine bleeding. The Annual Clinical Meeting of the American College of Obstetrics & Gynecology, 2001. e-Pub 2001.
68. Jazaeri AA, Nunes KJ, Rice LW. Estrogen and progesterone receptor mRNA expression in normal endometrium, and grade I endometrial adenocarcinoma, and malignant mixed mullerian tumors. 32nd Annual Meeting of the Society of Gynecologic Oncologists, 2001. e-Pub 2001.
69. Sotiriou C, Khanna C, Petersen D, Jazaeri AA, Liu ET. Core biopsy versus surgical tumor specimen for microarray analysis of gene expression profile. 92nd Annual Meeting of the American Association for Cancer Research, 2001. e-Pub 2001.
70. Jazaeri AA, Kim Y, McBride AW, Dalton SM, Rice LW. Cross-talk between estrogen and EGF pathways directs transcription in endometrial cancer cells. 32nd Annual Meeting of the Society of Gynecologic Oncologists, 2001. e-Pub 2001.
71. Jazaeri AA, Lu K, Sotirious C, Alkharouf N, Gershenson DM, Liu ET. The use of cDNA microarrays in the evaluation of ovarian cancer. Annual Meeting of the Society for Gynecologic Investigations, 2001. e-Pub 2001.
72. Jazaeri AA, Lu K, Sotirious C, Alkharouf N, Gershenson DM, Liu ET. Gene expression profiles of low and high grade papillary serous ovarian carcinomas using cDNA microarray analysis. AACR Nature Genetics Joint Conference, Oncogenomics: Dissecting cancer through genome research, 2001. e-Pub 2001.

Book Chapters

1. Ring KL, Brown J, AA J. Ovarian Cancer. In: The MD Anderson Manual of Medical Oncology. Third Edition, 2016.
2. Maxwell GL, AA J, Rice LW. “Hormones in Gynecologic Malignancies and Hormone Replacement Therapy”. In: Principles and Practice of Gynecologic Oncology. Fifth Edition, 2009.
3. AA J, Maxwell GL, Rice LW. “Hormones in Gynecologic Malignancies and Hormone Replacement Therapy”. In: Principles and Practice of Gynecologic Oncology. Fourth Edition, 2005.
4. Nitecki R, Cobb L, Rauh-Hain A, and Jazaeri AA. Ovarian Cancer. In: The MD Anderson Manual of Medical Oncology. Fourth Edition. McGraw-Hill.